Literature DB >> 26607597

Deletion of Rb1 induces both hyperproliferation and cell death in murine germinal center B cells.

Zhiwen He1, Julie O'Neal1, William C Wilson1, Nitin Mahajan1, Jun Luo1, Yinan Wang2, Mack Y Su1, Lan Lu1, James B Skeath3, Deepta Bhattacharya2, Michael H Tomasson4.   

Abstract

The retinoblastoma gene (RB1) has been implicated as a tumor suppressor in multiple myeloma (MM), yet its role remains unclear because in the majority of cases with 13q14 deletions, un-mutated RB1 remains expressed from the retained allele. To explore the role of Rb1 in MM, we examined the functional consequences of single- and double-copy Rb1 loss in germinal center B cells, the cells of origin of MM. We generated mice without Rb1 function in germinal center B cells by crossing Rb1(Flox/Flox) with C-γ-1-Cre (Cγ1) mice expressing the Cre recombinase in class-switched B cells in a p107(-/-) background to prevent p107 from compensating for Rb1 loss (Cγ1-Rb1(F/F)-p107(-/-)). All mice developed normally, but B cells with two copies of Rb1 deleted (Cγ1-Rb1(F/F)-p107(-/-)) exhibited increased proliferation and cell death compared with Cγ1-Rb1(+/+)-p107(-/-) controls ex vivo. In vivo, Cγ1-Rb1(F/F)-p107(-/-) mice had a lower percentage of splenic B220+ cells and reduced numbers of bone marrow antigen-specific secreting cells compared with control mice. Our data indicate that Rb1 loss induces both cell proliferation and death in germinal center B cells. Because no B-cell malignancies developed after 1 year of observation, our data also suggest that Rb1 loss is not sufficient to transform post-germinal center B cells and that additional, specific mutations are likely required to cooperate with Rb1 loss to induce malignant transformation.
Copyright © 2016 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26607597      PMCID: PMC4789175          DOI: 10.1016/j.exphem.2015.11.006

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  24 in total

1.  Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization.

Authors:  J Sage; G J Mulligan; L D Attardi; A Miller; S Chen; B Williams; E Theodorou; T Jacks
Journal:  Genes Dev       Date:  2000-12-01       Impact factor: 11.361

2.  Effects of an Rb mutation in the mouse.

Authors:  T Jacks; A Fazeli; E M Schmitt; R T Bronson; M A Goodell; R A Weinberg
Journal:  Nature       Date:  1992-09-24       Impact factor: 49.962

3.  Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization.

Authors:  N Zojer; R Königsberg; J Ackermann; E Fritz; S Dallinger; E Krömer; H Kaufmann; L Riedl; H Gisslinger; S Schreiber; R Heinz; H Ludwig; H Huber; J Drach
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

Review 4.  The retinoblastoma tumour suppressor in development and cancer.

Authors:  Marie Classon; Ed Harlow
Journal:  Nat Rev Cancer       Date:  2002-12       Impact factor: 60.716

5.  Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry.

Authors:  Julien Sage; Abigail L Miller; Pedro A Pérez-Mancera; Julianne M Wysocki; Tyler Jacks
Journal:  Nature       Date:  2003-07-10       Impact factor: 49.962

6.  Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis.

Authors:  E Y Lee; C Y Chang; N Hu; Y C Wang; C C Lai; K Herrup; W H Lee; A Bradley
Journal:  Nature       Date:  1992-09-24       Impact factor: 49.962

7.  The retinoblastoma gene (RB-1) status in multiple myeloma: a report on 35 cases.

Authors:  M Zandecki; T Facon; C Preudhomme; M Vanrumbeke; A Vachee; B Quesnel; J L Lai; A Cosson; P Fenaux
Journal:  Leuk Lymphoma       Date:  1995-08

8.  Deletion of the retinoblastoma gene in multiple myeloma.

Authors:  D D Dao; J R Sawyer; J Epstein; R G Hoover; B Barlogie; G Tricot
Journal:  Leukemia       Date:  1994-08       Impact factor: 11.528

9.  High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells.

Authors:  N Juge-Morineau; M P Mellerin; S Francois; M J Rapp; J L Harousseau; M Amiot; R Bataille
Journal:  Br J Haematol       Date:  1995-11       Impact factor: 6.998

10.  Targeted disruption of p107: functional overlap between p107 and Rb.

Authors:  M H Lee; B O Williams; G Mulligan; S Mukai; R T Bronson; N Dyson; E Harlow; T Jacks
Journal:  Genes Dev       Date:  1996-07-01       Impact factor: 11.361

View more
  4 in total

1.  Sabotaging of the oxidative stress response by an oncogenic noncoding RNA.

Authors:  Nitin Mahajan; Hua-Jun Wu; Richard L Bennett; Catalina Troche; Jonathan D Licht; Jason D Weber; Leonard B Maggi; Michael H Tomasson
Journal:  FASEB J       Date:  2016-10-24       Impact factor: 5.191

Review 2.  Virus-Mediated Inhibition of Apoptosis in the Context of EBV-Associated Diseases: Molecular Mechanisms and Therapeutic Perspectives.

Authors:  Zbigniew Wyżewski; Matylda Barbara Mielcarska; Karolina Paulina Gregorczyk-Zboroch; Anna Myszka
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

3.  Refractory multiple myeloma with extramedullary plasmacytoma of the spleen and suspicious teratoma: a rare case report and literature review.

Authors:  Peipei Xu; Hong Chu; Xiaoyan Shao; Ying Jiang; Chaoyang Guan; Ming Chen; Bing Chen
Journal:  Int J Clin Exp Pathol       Date:  2021-04-15

4.  Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma.

Authors:  Chunyan Gu; Xuefang Jing; Carol Holman; Ramakrishna Sompallae; Fenghuang Zhan; Guido Tricot; Ye Yang; Siegfried Janz
Journal:  BMC Cancer       Date:  2018-11-21       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.